Products

The Problem

Infertility remains one of the major unmet medical needs globally.

In the United States, infertility affects around 13-15% of reproductive-aged couples, and the number of women treated for infertility per year is around 1.7 million. Assisted reproductive technology (ART) includes all fertility treatments with the main type of ART being in vitro fertilization (IVF). As part of ART, supplementation of progesterone (PRO) promotes fertility, prevents miscarriages and even prevents pre-term labor.

Current available options for PRO supplementation are limited to messy vaginal gel (Crinone®) and inserts (Endometrin®) that require administration 2-3 times per day, or painful daily IM injections that require another person’s help to administer and have side effects such as abscess formation.

Infertility in the US

The AnelleO Solution

The AnelleO solution offers progesterone supplementation with an intravaginal ring (IVR), providing a patient friendly option of a single patient-administered ring delivering PRO for the entire 8-10 week course.  Utilizing state-of-the-art 3D printing technology, AnelleO can design and manufacture an IVR-based product that will

  1. Release progesterone over extended periods of time (≥30 days) to cover the entire ART period,

  2. Enhance patient compliance with an efficient and patient friendly treatment, and

  3. Match or exceed efficacy of current technologies for PRO supplementation in ART.

Therefore, development of a long-acting progesterone IVR will be ground breaking, as there is no FDA approved IVR to deliver natural progesterone to cover the entire ART period with one ring.

AnelleO is harnessing the advancements in the speed and scale of 3D printing technology for novel solutions in Women’s Health. AnelleO’s first products are Intravaginal Rings (IVRs), which offer a unique platform for sustained delivery of therapeutics – a non-invasive, self-administered and retrievable platform that can deliver drugs over a period of weeks or months.

Contact us at: [email protected]
Legal Information: Conflict of Interest Policy